Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mometasone furoate + azelastine is a fixed-dose combination nasal spray used primarily for the treatment of allergic rhinitis, including both seasonal and perennial forms. It combines two active ingredients with complementary mechanisms of action. Mometasone furoate is a corticosteroid that reduces inflammation by inhibiting the production of inflammatory mediators such as prostaglandins, thereby relieving symptoms like swelling and itching. Azelastine is an antihistamine that acts as a histamine H1-receptor antagonist, blocking the effects of histamine released during allergic reactions to reduce sneezing, runny nose, and itching. This combination provides rapid and sustained relief from nasal allergy symptoms[1][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mometasone furoate + azelastine.